Stock info Astrazeneca | Filter  Basic-Info

Astrazeneca

The past year yielded positive returns for Astrazeneca investors

The stock lost over the past 12 months at around 2 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 50 percent. Astrazeneca's revenues between 2011 and 2015 were relatively steady and moved between 1721,32 billion GBp and 1676,49 billion GBp. Astrazeneca's net results between 2011 and 2015 were quite unstable and moved between 563,16 billion GBp and 283,62 billion GBp.

Astrazeneca has it' headquarter based in London. Astrazeneca is mostly active in the pharmaceutical sector. The past 10 years the (international) industry gained at around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-2016) there is a minus of 75 percent.

Over the past 5 years the English company paid out dividends. On average Astrazeneca's dividend yield over the past 5 years was around 1008,36 percent annually. Over the period 2011-2015 Astrazeneca raised it's dividends per share each year. So because of the yearly raised dividends per share Astrazeneca is a kind of dividend aristocrat.

Astrazeneca' balance mostly financed with equity

At the end of 2015 the pharmaceutical company's balance sheet was worth 4079,53 billion GBp. At the end of 2015 the total debt positon equaled 2824,95 billion GBp. This is around 69,25 percent of the total balance sheet. At the end of 2015 the pharmaceutical company's stock was traded with a price/earnings-ratio 20. So the stock' value was 20 times the 2015' earnings per share. We could say that based on her price/earnings-ratio and dividend yield the English stock can be seen as a value stock.

At the end of 2015 the English company's market capitalization equaled around 5835,26 billion GBp. At the end of 2015 around 1,26 billion stocks were listed.

All of Astrazeneca's annual reports are stored here. More information about Astrazeneca can be found it's website. .